Cargando…
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
OBJECTIVE: To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. METHODS: A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to sever...
Autores principales: | Khamis, Faryal, Al Naabi, Hanan, Al Lawati, Adil, Ambusaidi, Zaiyana, Al Sharji, Mariam, Al Barwani, Umkulthum, Pandak, Nenad, Al Balushi, Zakariya, Al Bahrani, Maher, Al Salmi, Issa, Al-Zakwani, Ibrahim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833906/ https://www.ncbi.nlm.nih.gov/pubmed/33181328 http://dx.doi.org/10.1016/j.ijid.2020.11.008 |
Ejemplares similares
-
Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial
por: Khamis, Faryal, et al.
Publicado: (2021) -
Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection
por: Khamis, Faryal, et al.
Publicado: (2021) -
Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman
por: Khamis, Faryal, et al.
Publicado: (2020) -
The Impact of Demographic, Clinical Characteristics and the Various COVID-19 Variant Types on All-Cause Mortality: A Case-Series Retrospective Study
por: Khamis, Faryal, et al.
Publicado: (2022) -
Immunological predictors of disease severity in patients with COVID-19
por: Al Balushi, Asma, et al.
Publicado: (2021)